Skip to content

Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01994681
Enrollment
100
Registered
2013-11-26
Start date
2013-10-31
Completion date
Unknown
Last updated
2013-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Brief summary

Volatile Organic Compounds (VOC) in human breath are captured and analyzed by the Spectrosense EVA system, which is combination of a gas chromatography (GC) and software algorithm. The objective is to obtain a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population. The gold standard for identifying sick/healthy population is biopsy proven Pancreatic cancer.

Interventions

None listed

Sponsors

Spectrosense Ltd.
CollaboratorINDUSTRY
Rauscher, Gregory E., M.D. PA
Lead SponsorINDIV

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Pancreatic cancer Group Inclusion Criteria: * Age from 18 years old * Pancreatic cancer positive biopsy * Before any treatment * Signed Informed Patient Consent

Exclusion criteria

* Age under 18 years old * Neoadjovant treatment * Post surgery for Pancreatic cancer * A history of any other cancer type, except skin cancer that is not melanoma Healthy Group Inclusion Criteria: * Healthy patients * No history of Pancreatic cancer * Signed Informed Patient Consent

Design outcomes

Primary

MeasureTime frameDescription
Obtaining a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population.BaselineAn optimization algorithm will select VOCs that will provide maximal sensitivity and specificity.

Countries

United States

Contacts

Primary ContactKevin Barga
kbarga@hackensackumc.org(551)996-8017

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026